Technology and services provider Althea Technologies has stepped
closer to a significant increase in manufacturing capacity as it
announces the completion of the first phase of construction at its
new San Diego facility.
Swiss contract manufacturer Lonza has announced it will invest
around $300m (€220m) in the expansion of its US biomanufacturing
plant, just two weeks after kicking off the construction of a
similar facility in Singapore.
A Brazilian firm has signed a licensing deal to take advantage of a
biopharmaceutical manufacturing technology which will allow the
company to locally manufacture complex biopharmaceuticals destined
for the South American market.
This week Lonza took over the reigns of two new US business units
from Cambrex after completing the largest acquisition in its
company history and also announced a capability expansion at its
Czech Republic site.
US-based firm Xcellerex yesterday announced it has completed the
second half of a $20m (€15.4m) financing deal, raising $11m to
speed up commercialisation of its innovative disposable
manufacturing technology for vaccines and biotherapeutics.
The European Commission continues to be accused by European
industry of pushing 'green policies' that are stifling progress and
global competitiveness - the controversial REACH chemicals
legislation remains a sore point.